Morgan Stanley has increased its price target for AstraZeneca, signaling continued confidence in the pharmaceutical giant. This adjustment reflects a positive outlook on the company’s performance within the broader European pharmaceuticals sector.
AstraZeneca Price Target Raised
The revised price target, moving from $93 to $103, represents a potential upside of approximately 10.75% from the previous target. This announcement has not yet resulted in observable market movement.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Morgan Stanley’s analysis indicates a neutral stance on the EU Pharmaceuticals sector as a whole heading into 2026. The firm notes that the sector’s fundamentals remain strong, and valuation premiums are low relative to historical levels. However, this is tempered by the expectation of stronger earnings per share (EPS) growth in other European sectors.
The Morgan Stanley analyst wrote in a year-ahead outlook note that the EU Pharmaceuticals sector is neither particularly attractive nor unattractive, with solid fundamentals being offset by better growth opportunities elsewhere.
The upgrade suggests confidence in AstraZeneca’s specific pipeline, market positioning, and strategic initiatives.
AZN Analyst Summary
Bull Case
- Strong fundamentals in EU Pharmaceuticals sector, low valuation premiums.
- AstraZeneca specific pipeline.
- Morgan Stanley “Overweight” rating affirms confidence in AstraZeneca.
Bear Case
- Better EPS growth expected in other European sectors.
- Clinical trial outcomes uncertain, impact valuation.
- Regulatory approvals of new drugs can be lengthy.
AstraZeneca faces both opportunities and challenges. The company’s success will depend on factors such as clinical trial outcomes, regulatory approvals, and competitive dynamics.
